• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23847 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Universal, community-based developmental screening tools for children 6 years and younger: a review of clinical effectiveness
2020     NIHR Health Technology Assessment programme Unspecified living kidney donation in the UK: barriers to implementation and delivery
2022     Institute for Clinical and Economic Review (ICER) Unsupported price increase report: unsupported price increases occurring in 2021
2024     Institute for Clinical and Economic Review (ICER) Unsupported price increase report: unsupported price increases occurring in 2023
2023     National Institute for Health and Care Excellence (NICE) Upadacitinib for previously treated moderately to severely active Crohn's disease. NICE technology appraisal guidance 905
2021     Scottish Medicines Consortium (SMC) Upadacitinib for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs)
2022     National Institute for Health and Care Excellence (NICE) Upadacitinib for treating active ankylosing spondylitis. NICE technology appraisal guidance 829
2023     National Institute for Health and Care Excellence (NICE) Upadacitinib for treating active non-radiographic axial spondyloarthritis. NICE technology appraisal guidance 861
2022     National Institute for Health and Care Excellence (NICE) Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 768
2021     National Institute for Health and Care Excellence (NICE) Upadacitinib for treating moderate rheumatoid arthritis. NICE technology appraisal guidance 744
2023     National Institute for Health and Care Excellence (NICE) Upadacitinib for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 856
2020     National Institute for Health and Care Excellence (NICE) Upadacitinib for treating severe rheumatoid arthritis. NICE technology appraisal guidance 665
2020     Austrian Institute for Health Technology Assessment (AIHTA) Update 12 months follow-up: Nusinersen in spinal muscular atrophy ("late onset") in children and adolescents ≥ 6 years
2025     Belgian Health Care Knowledge Centre (KCE) Update of breast cancer screening recommendations (Study 2024-11)
2022     Agency for Care Effectiveness (ACE) Update of MOH list of subsidised drugs to include treatments for various cancer conditions
2025     Belgian Health Care Knowledge Centre (KCE) Update of prostate cancer screening recommendations (Study 2024-10)
2007     Andalusian Health Technology Assessment Area (AETSA) Update of the guidance for the introduction of new drugs
2007     Andalusian Health Technology Assessment Area (AETSA) Update of the guide for acquisition of new technologies (GANT)
2016     Andalusian Health Technology Assessment Area (AETSA) Update of the Guide for decision-making on the introduction of new genetic tests in the National Health System (GEN Guide)
2007     Andalusian Health Technology Assessment Area (AETSA) Update of the guide for the acquisition of new technologies
2007     Andalusian Health Technology Assessment Area (AETSA) Update of the guide for the introduction of new drugs (GINF)
2012     Belgian Health Care Knowledge Centre (KCE) Update of the national guideline on upper gastrointestinal cancer
2005     Agency for Healthcare Research and Quality (AHRQ) Update on acute bacterial rhinosinusitis
2013     Agency for Healthcare Research and Quality (AHRQ) Update on emerging genetic tests currently available for clinical use in common cancers
2011     Agency for Healthcare Research and Quality (AHRQ) Update on horizon scans of genetic tests currently available for clinical use in cancers
2012     Agency for Healthcare Research and Quality (AHRQ) Update on mapping the landscape of genetic tests for non-cancer diseases/conditions
2014     Health Quality Ontario (HQO) Update on physiotherapy rehabilitation after total knee or hip replacement
2020     Austrian Institute for Health Technology Assessment (AIHTA) Update PET/PET-CT evidence for need based planning in the area of oncology
2022     Health Information and Quality Authority (HIQA) Update processes for guidelines – systematic review
2003     Wessex Institute for Health Research and Development (WIHRD) Update report: Effects of desensitisation treatments and clinical ecology for multiple chemical sensitivity and related disorders
2002     Wessex Institute for Health Research and Development (WIHRD) Update report: Non-myeloablative bone marrow and peripheral blood stem cell transplant
2018     Penn Medicine Center for Evidence-based Practice (CEP) Update: Anticoagulation Management in Paracentesis and Thoracentesis
2018     Penn Medicine Center for Evidence-based Practice (CEP) Update: Best practices for central venous catheter removal
2020     The Regional Health Technology Assessment Centre (HTA-centrum) Update: Chlorhexidine wash prior to clean surgical procedures
2023     Penn Medicine Center for Evidence-based Practice (CEP) Update: Clinical risk prediction tools for venous thromboembolism in medical patients
2014     Penn Medicine Center for Evidence-based Practice (CEP) Update: Cognitive and procedural skills of aging physicians
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Update: guidelines on the preoperative diagnostic workup for COVID-19
2017     NIHR Health Services and Delivery Research programme Updated meta-review of evidence on support for carers
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Updated reports and recommendations on second- and third-line therapies for type 2 diabetes
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: Alair® bronchial thermoplasty system for severe asthma
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: Amniotic fluid lactate™ monitoring system for dysfunctional labour
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: Argus II™ retinal prosthesis system for peripheral retinal degeneration
2013     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: Caris Target Now™ molecular profiling service for solid malignant tumours
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: DuoFertility ovulation prediction system to aid natural conception
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: Infrared lasers for treating onychomycosis
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: OVA1™ test for the assessment of suspected ovarian cancer
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: Placental growth factor based tests for the diagnosis of pre-eclampsia
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: RealTime mS9 Colorectal Cancer (CRC) Assay for the early detection of colorectal cancer
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: RhinoChill® intranasal cooling device for protective cooling the brain after a cerebral ischaemic event
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: SoundBite™ hearing system
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: SpringTMS™ Total Migraine System
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: ThromboLUX™ for determining platelet quality
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: VERV™ patient managed transdermal neuromodulation system for overactive bladder syndrome
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: Xpert MTB/RIF® test for tuberculosis
2007     Agency for Healthcare Research and Quality (AHRQ) Updating systematic reviews
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Upper airway stimulation for moderate-to-severe sleep apnea
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Upper Airway Stimulation for Moderate-to-Severe Sleep Apnea. 1st Update 2019
2022     Austrian Institute for Health Technology Assessment (AIHTA) Upper airway stimulation for moderate-to-severe sleep apnoea. Update 2022
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Upper extremity deep vein thrombosis with peripherally inserted central catheters: a review of the guidelines
2018     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Upper gastrointestinal endoscopy categorisation guidelines for adults
2008     HAYES, Inc. Upright magnetic resonance imaging (MRI) for diagnosis of spinal disorders
2014     HAYES, Inc. Upright magnetic resonance imaging for diagnosis of spinal disorders
2005     Institute for Clinical Evaluative Sciences (ICES) Uptake and outcomes associated with cyclooxygenase (COX-2) inhibitors in Ontario's elderly
1997     Scottish Health Purchasing Information Centre (SHPIC) Uptake of breast cancer screening
2024     Austrian Institute for Health Technology Assessment (AIHTA) Uptake of mental health benefits in before and during the perinatal period: an analysis of Austrian health insurance data
2011     Institute for Clinical Evaluative Sciences (ICES) Uptake of the new fee code for Ontario's enhanced 18-month well baby visit: a preliminary evaluation
1998     ECRI Urea breath tests for detecting helicobacter pylori
2007     HAYES, Inc. Ureteral bulking agents for vesicoureteral reflux disease
2019     National Institute for Health and Care Excellence (NICE) UrgoStart for treating diabetic foot ulcers and leg ulcers. NICE medical technologies guidance 42
2014     Penn Medicine Center for Evidence-based Practice (CEP) Urinalysis and urine culture specimens taken from old versus new urinary catheters in patients with suspected urinary tract infection
2024     Penn Medicine Center for Evidence-based Practice (CEP) Urinary catheter exchange prior to sample collection 2024 update
2024     Penn Medicine Center for Evidence-based Practice (CEP) Urinary catheterization for epidural anesthesia in obstetrics
2010     HAYES, Inc. Urinary cross-linked N-telopeptide of type I collagen biomarker for diagnosis of osteoporosis and fracture risk assessment
2010     HAYES, Inc. Urinary cross-linked N-telopeptide of type I collagen biomarker for management of osteoporosis treatment
2001     Health Council of the Netherlands Gezondheidsraad (GR) Urinary incontinence - review, expert panel
2008     Medical Services Advisory Committee (MSAC) Urinary metabolic profile
2008     Medical Services Advisory Committee (MSAC) Urinary metabolic profiling for detection of metabolic disorders
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Urine based testing for gonorrhea and chlamydia: a review of diagnostic accuracy, cost-effectiveness, and compliance
2013     Penn Medicine Center for Evidence-based Practice (CEP) Urine drug screening in chronic pain patients on opioid therapy
2010     Penn Medicine Center for Evidence-based Practice (CEP) Urine drug screening in chronic pain patients on opioid therapy
2023     Penn Medicine Center for Evidence-based Practice (CEP) Urine pregnancy screening for patients with and without the capacity for pregnancy
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Urine testing in long-term care: clinical and cost effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Urine testing in long-term care: guidelines
2020     NIHR Health Technology Assessment programme Urodynamics tests for the diagnosis and management of bladder outlet obstruction in men: the UPSTREAM non-inferiority RCT
2021     National Institute for Health and Care Excellence (NICE) UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia. NICE medical technologies guidance 58
2017     HAYES, Inc. Urolift system (NeoTract Inc.) for treatment of benign prostatic hyperplasia
2016     HAYES, Inc. UroLift System (NeoTract Inc.) for treatment of benign prostatic hyperplasia
2011     HAYES, Inc. UroLume urethral stent (American Medical Systems Inc.) for urinary obstruction secondary to benign prostatic hyperplasia (BPH)
2022     National Institute for Health and Care Excellence (NICE) UroShield for preventing catheter-associated urinary tract infections. NICE medical technologies guidance 69
2016     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Ursodeoxycholic acid (Ursofalk®)
2020     Agency for Care Effectiveness (ACE) Ursodeoxycholic acid for treating primary biliary cirrhosis
2020     NIHR Health Technology Assessment programme Ursodeoxycholic acid to reduce adverse perinatal outcomes for intrahepatic cholestasis of pregnancy: the PITCHES RCT
2006     Adelaide Health Technology Assessment (AHTA) USCOM cardiac output monitor for patients requiring haemodynamic monitoring
2005     Adelaide Health Technology Assessment (AHTA) USCOM cardiac output monitor for ultrasonic cardiac output measurement in patients requiring haemodynamic monitoring
2006     Alberta Heritage Foundation for Medical Research (AHFMR) USCOM for cardiac output monitoring
2007     Adelaide Health Technology Assessment (AHTA) USCOM: Ultrasound cardiac output monitor for patients requiring haemodynamic monitoring
2006     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Use of adalimumab (Humira®) within NHS Wales
2006     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Use of agalsidase beta (Fabrazyme®) within NHS Wales
2007     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Use of alglucosidase alfa (Myozyme™) within NHS Wales
2010     HAYES, Inc. Use of anti-infliximab antibody levels to monitor infliximab treatment